Biogen Inc. $BIIB Stock Holdings Increased by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co lifted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 1,401.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 261,333 shares of the biotechnology company’s stock after purchasing an additional 243,933 shares during the period. Biogen accounts for about 0.4% of Ilmarinen Mutual Pension Insurance Co’s investment portfolio, making the stock its 28th biggest holding. Ilmarinen Mutual Pension Insurance Co owned approximately 0.18% of Biogen worth $59,030,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Bell Investment Advisors Inc acquired a new position in Biogen during the second quarter valued at approximately $27,000. Align Financial LLC lifted its position in Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 95 shares during the last quarter. Provenance Wealth Advisors LLC bought a new stake in Biogen during the third quarter valued at about $29,000. Canton Hathaway LLC acquired a new stake in Biogen in the 3rd quarter valued at approximately $31,000. Finally, Financial Freedom LLC bought a new position in Biogen in the 3rd quarter worth approximately $34,000. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Seaport Research Partners upgraded shares of Biogen to an “outperform” rating in a report on Monday, October 12th. Oppenheimer reiterated an “outperform” rating and issued a $300.00 price objective on shares of Biogen in a research note on Wednesday, July 29th. JPMorgan Chase & Co. upgraded shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $210.00 to $300.00 in a research note on Monday, October 12th. Wall Street Zen raised shares of Biogen from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 14th. Finally, Weiss Ratings cut Biogen from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $255.45.

View Our Latest Stock Analysis on Biogen

Biogen Trading Up 1.0%

Shares of NASDAQ:BIIB opened at $249.59 on Friday. The company has a 50-day simple moving average of $236.83 and a 200 day simple moving average of $206.86. The company has a market capitalization of $36.89 billion, a P/E ratio of 106.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. During the same quarter in the previous year, the firm posted $4.81 EPS. Biogen’s revenue was up 10.6% compared to the same quarter last year. Sell-side analysts forecast that Biogen Inc. will post 12.46 earnings per share for the current year.

Biogen News Roundup

These are some of the BIIB news items that stood out recently:

  • Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with α-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
  • Neutral Sentiment: Analyst commentary is mixed overall: one report says analysts remain moderately upbeat and notes BIIB has outpaced broad benchmarks over the past year, while another says Alzheimer’s progress and M&A-related growth expectations may already be reflected in the valuation. Analyst outlook Rating downgrade
  • Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article

About Biogen

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Recommended Stories

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.